TSVT
2seventy bio, Inc.
Industry
Biotechnology
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.
Loading...
Open
5.02
Mkt cap
254M
Volume
43K
High
5.04
P/E Ratio
-1.53
52-wk high
6.40
Low
4.88
Div yield
N/A
52-wk low
1.53

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.